Sarepta Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A maker of precision genetic medicines for rare diseases, Sarepta Therapeutics develops treatments for Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, including Exondys 51, the first therapy ever approved for DMD. The company began in 1980 in Corvallis, Oregon, as AntiVirals, Inc., later became AVI BioPharma, and took the name Sarepta in 2012. The name comes from the biblical town of Sarepta, where the prophet Elijah performed miracles.
1.5% Convertible Senior Notes due November 15, 2024 — Matured November 15, 2024
Bought 2.14M · Sold 640.0K
Sold 4.43M
Granted 70.0K · Bought 140.0K · Sold 135.0K
Granted 21.4K · Sold 119.0K
Granted 874.1K · Bought 184.4K
Granted 2.41M · Sold 1.69M
Granted 27.5K · Bought 208.8K
Granted 28.9K
Granted 263.0K · Bought 3.8K
Granted 137.8K · Bought 201.5K · Sold 15.0K
Granted 246.3K · Sold 20.4K
Granted 7.5K
Granted 129.2K
Granted 118.9K
Granted 35.7K
Granted 383.7K · Sold 329.4K
Granted 7.2K
Granted 218.5K · Bought 800 · Sold 99.1K
Granted 46.3K · Bought 24.0K
Granted 8.8K · Bought 265.6K · Sold 53.0K
Granted 60.0K
Granted 57.7K · Sold 2.5K
Granted 14.8K · Bought 163.0K
Granted 140.1K · Sold 93.8K
Granted 37.4K · Sold 50.9K
Granted 57.7K · Sold 40.9K
Granted 619.3K · Bought 5.0K · Sold 442.5K
Granted 37.5K · Sold 3.6K
Granted 81.7K · Bought 430.8K
Granted 33.7K
Granted 27.5K · Sold 2.4K
Granted 42.5K · Sold 13.8K
Granted 63.3K · Sold 41.0K
Granted 22.1K
Granted 23.0K
Granted 29.9K · Sold 11.2K
Granted 12.3K
Granted 105.2K · Sold 96.7K
Granted 7.1K · Bought 2.0K
Granted 14.8K
Granted 3.4K · Sold 3.4K
Granted 7.9K
Granted 7.5K
Granted 19.4K · Sold 5.6K
Bought 5.0K
Granted 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Haywood George WeaverSee remarks below · 30 transactions | — | 9.24Mas of Aug 2009 | — | 2.14M | 640.0K |
| Eastbourne Capital Management LLC/CA10% owner · 5 transactions | — | 5.66Mas of Mar 2010 | — | — | 4.43M |
| Barry RichardDirector · 28 transactions | — | 3.23M | 70.0K | 140.0K | 135.0K |
| kole RyszardSVP/Discovery Research · 5 transactions | — | 1.86Mas of Feb 2010 | 21.4K | — | 119.0K |
| Ingram Douglas SChief Executive Officer, Director · 22 transactions | — | 659.8K | 874.1K | 184.4K | — |
| Hudson LeslieFormer CEO · 65 transactions | — | 568.0Kas of Jul 2010 | 2.41M | — | 1.69M |
| Chambers Michael AndrewDirector · 19 transactions | — | 504.0K | 27.5K | 208.8K | — |
| Weller Dwight DSr. VP Chemistry & Mfg. · 1 transaction | — | 364.6Kas of Feb 2010 | 28.9K | — | — |
| Rodino-Klapac LouisePresident, R&D and Tech Ops · 39 transactions | — | 225.3K | 263.0K | 3.8K | — |
| Behrens M KathleenDirector · 37 transactions | — | 224.4K | 137.8K | 201.5K | 15.0K |
| Estepan Ian MichaelChief Operating Officer · 45 transactions | — | 202.0K | 246.3K | — | 20.4K |
| Burger Denis RCEO, Director · 2 transactions | — | 171.0Kas of Nov 2006 | 7.5K | — | — |
| Rothfuss CristinEVP, General Counsel · 15 transactions | — | 137.5K | 129.2K | — | — |
| Wong Ryan Ho-YanChief Financial Officer · 9 transactions | — | 135.1K | 118.9K | — | — |
| Iversen Patrick LSr VP of Research & Devlopment · 5 transactions | — | 98.3Kas of Feb 2010 | 35.7K | — | — |
| Howton David TEVP, General Counsel · 64 transactions | — | 92.0Kas of Jun 2020 | 383.7K | — | 329.4K |
| Timmins Alan PPresident & COO, Director · 2 transactions | — | 71.4Kas of Mar 2008 | 7.2K | — | — |
| Kaye Edward M. MDDirector · 26 transactions | — | 71.2Kas of Aug 2017 | 218.5K | 800 | 99.1K |
| Boyle J David IICEO · 3 transactions | — | 70.3Kas of Aug 2010 | 46.3K | 24.0K | — |
| Chase Anthony RDirector · 31 transactions | — | 67.2Kas of Feb 2015 | 8.8K | 265.6K | 53.0K |
| Shrewsbury Stephen BSVP/Regulatory Affairs · 1 transaction | — | 60.0Kas of Feb 2010 | 60.0K | — | — |
| Nicaise ClaudeDirector · 15 transactions | — | 48.4K | 57.7K | — | 2.5K |
| Price Ben GilDirector · 17 transactions | — | 42.8Kas of Mar 2016 | 14.8K | 163.0K | — |
| Wigzell Hans Lennart RudolfDirector · 41 transactions | — | 42.1K | 140.1K | — | 93.8K |
| Aphale JayantVP, Technical Operations · 7 transactions | — | 37.0Kas of Sep 2016 | 37.4K | — | 50.9K |
| Ruff ShamimSVP, Chief Regulatory Affairs · 22 transactions | — | 33.2Kas of May 2018 | 57.7K | — | 40.9K |
| Mahatme SandeshEVP, CFO & CBO · 67 transactions | — | 32.3Kas of Jul 2020 | 619.3K | 5.0K | 442.5K |
| Murray DallanChief Customer Officer · 12 transactions | — | 29.9Kas of Mar 2025 | 37.5K | — | 3.6K |
| Christopher Nishan GarabedianPresident and CEO, Director · 4 transactions | — | 29.6Kas of Feb 2015 | 81.7K | 430.8K | — |
| O'Neill Gilmore NeilEVP, R&D & CMO · 5 transactions | — | 28.5Kas of Mar 2021 | 33.7K | — | — |
| Boor Kathryn JeanDirector · 7 transactions | — | 25.1K | 27.5K | — | 2.4K |
| Arif BilalChief Tech Ops Officer · 33 transactions | — | 24.2Kas of Mar 2025 | 42.5K | — | 13.8K |
| Brown Ryan EdwardEVP, General Counsel · 31 transactions | — | 23.5Kas of Jun 2024 | 63.3K | — | 41.0K |
| Connelly Deirdre PDirector · 3 transactions | — | 22.1K | 22.1K | — | — |
| Ciambrone WilliamEVP · 3 transactions | — | 22.1Kas of Mar 2022 | 23.0K | — | — |
| Mayo StephenDirector · 9 transactions | — | 18.6K | 29.9K | — | 11.2K |
| Gray Mary AnnDirector · 7 transactions | — | 12.4Kas of Mar 2022 | 12.3K | — | — |
| Cumbo AlexanderEVP, Chief Commercial Officer · 34 transactions | — | 12.0Kas of Feb 2020 | 105.2K | — | 96.7K |
| Bonney Michael WDirector · 4 transactions | — | 9.1Kas of Feb 2020 | 7.1K | 2.0K | — |
| Goolsbee William AldenDirector · 7 transactions | — | 8.2Kas of Feb 2016 | 14.8K | — | — |
| Bratica JosephPrincipal Financial Officer · 6 transactions | — | 8.1Kas of Dec 2020 | 3.4K | — | 3.4K |
| Martin John CDirector · 3 transactions | — | 7.9Kas of Mar 2021 | 7.9K | — | — |
| Jacobsen Michael AVP of Finance and PAO · 1 transaction | — | 7.5Kas of Aug 2012 | 7.5K | — | — |
| Hodgman JohnDirector · 8 transactions | — | 6.3Kas of Feb 2015 | 19.4K | — | 5.6K |
| Bowman Jack LDirector · 1 transaction | — | 5.0Kas of May 2007 | — | 5.0K | — |
| Kress Jean-PaulDirector · 2 transactions | — | 2.0Kas of Mar 2017 | 2.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.56M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.